公开(公告)号：AU2009327357A1

公开(公告)日：2011-07-28

申请号：AU2009327357

申请日：2009-12-18

Applicant: VERTEX PHARMA

Inventor： JEAN-DAMIEN CHARRIER ,  STEVEN DURRANT ,  DAVID KAY ,  RONALD KNEGTEL ,  SOMHAIRLE MACCORMICK ,  MICHAEL MORTIMORE ,  MICHAEL O'DONNELL ,  JOANNE PINDER ,  ALISTAIR RUTHERFORD ,  NIZARALI VIRANI ANISA ,  STEPHEN YOUNG ,  MICHAEL REAPER PHILIP

IPC: C07D413/04 ,  A61K31/497 ,  A61P35/00 ,  C07D401/14 ,  C07D403/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04

Abstract: The present invention relates to pyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula (I):wherein the variables are as defined herein.

公开(公告)号：AU2009313198A1

公开(公告)日：2011-06-30

申请号：AU2009313198

申请日：2009-11-10

Applicant: VERTEX PHARMA

Inventor： JEAN-DAMIEN CHARRIER ,  STEVEN DURRANT ,  DAVID KAY ,  MICHAEL O'DONNELL ,  RONALD KNEGTEL ,  SOMHAIRLE MACCORMICK ,  JOANNE PINDER ,  ANISA VIRANI ,  STEPHEN YOUNG ,  HAYLEY BINCH ,  THOMAS CLEVELAND ,  FANNING LEV T D ,  DENNIS HURLEY ,  PRAMOD JOSHI ,  URVI SHETH ,  ALINA SILINA ,  MICHAEL REAPER PHILIP

IPC: C07D401/04 ,  A61K31/4965 ,  A61P35/00 ,  C07D403/04 ,  C07D413/04

Abstract: The present disclosure relates to pyrazine compounds of formula (I) wherein L, n, R, and R are as described in the specification. These compounds are useful as inhibitors of ATR protein kinase. The disclosure also relates to pharmaceutically acceptable compositions comprising the compounds of the disclosure; methods of treating of various diseases, disorders, and conditions using the compounds of the disclosure; processes for preparing the compounds of the disclosure; intermediates for the preparation of the compounds of the disclosure; and methods of using the compounds in applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.